This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Neogen (NEOG) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Add Neogen (NEOG) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) on strength in its Food Safety and Animal Safety business segments.
Thermo Fisher (TMO) Expands Biologics Network With New Facility
by Zacks Equity Research
Thermo Fisher's (TMO) Lengnau site will offer biopharma companies a pathway from development to large-scale production.
NEOGEN (NEOG) Inks Genomic Selection Deal With Hendrix
by Zacks Equity Research
Hendrix Genetics with the help of NEOGEN's (NEOG) Genomics will be able to genotype the elite animals in the population.
NEOGEN (NEOG) Igenity Branded Calves Score Highest US Sales
by Zacks Equity Research
NEOGEN's (NEOG) Igenity-tested calves earn an average premium of over $59 in the summer selling season.
All You Need to Know About Neogen (NEOG) Rating Upgrade to Buy
by Zacks Equity Research
Neogen (NEOG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neogen (NEOG) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Strong segmental performance and contributions from new acquisitions and product launches drove Neogen's (NEOG) revenues in the first quarter of fiscal 2022.
Company News for Sep 22, 2021
by Zacks Equity Research
Companies In The News Are: UBER, ATVI, AZO, NEOG.
Neogen (NEOG) to Report Q1 Results: What You Should Expect
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEOGEN (NEOG) to Enter Retail Parasiticide Space With New Buyout
by Zacks Equity Research
NEOGEN's (NEOG) acquisition of CAPInnoVet expands its Animal Safety division and offers a strategic entry into the retail parasiticide market.
Neogen (NEOG) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 6.67% and 4.82%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Down 4.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Strong fiscal fourth-quarter performance in the Food Safety and Animal Safety segments drove the top line for Neogen (NEOG).
Neogen (NEOG) Misses Q4 Earnings, Tops Revenue Estimates
by Zacks Equity Research
Strong segmental revenues and solid international performance across Neogen's (NEOG) entire business drove its topline.
Neogen (NEOG) Lags Q4 Earnings Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -6.25% and 2.02%, respectively, for the quarter ended May 2021. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) to Report Q4 Results: What You Should Expect
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEOGEN (NEOG) Enhances Aquaculture Genotyping With New Pact
by Zacks Equity Research
NEOGEN (NEOG) together with CAT can enable members of the aquaculture sector to make more informed breeding decisions.
NEOGEN's (NEOG) Soleris Test to Serve the Cannabis Industry
by Zacks Equity Research
NEOGEN's (NEOG) Soleris Direct Yeast and Mold test is approved by the AOAC Institute to identify yeasts and molds in dried cannabis flower.
Neogen (NEOG) Up 13.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.
Neogen (NEOG) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance in both its Animal Safety and Food Safety segments during the fiscal third quarter pushes Neogen (NEOG) to a 52-week high.
NEOGEN's (NEOG) Earnings Miss Estimates in Q3, Margins Up
by Zacks Equity Research
NEOGEN's (NEOG) third-quarter fiscal 2021 revenues increase 16.9% year over year, driven by strong segmental growth and robust international business.
Neogen (NEOG) Q3 Earnings Miss Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -7.41% and 9.00%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEOGEN's (NEOG) New Test to Identify Coronavirus in Wastewater
by Zacks Equity Research
Launch of NEOGEN's (NEOG) latest test, which marks its entry into wastewater testing, is expected to become a key tool to combat COVID-19.